Abstract
The hospitalization and symptomatic rates of Severe Acute Respiratory Syndrome Coronavirus Disease 2019 (SARS-CoV-2) are key epidemiological parameters affecting risk analyses conducted for the Canadian Armed Forces (CAF) during the Coronavirus Disease-19 (COVID-19) pandemic. As one of the criteria of a variant of concern (VOC) is that it affects disease severity, the authors sought to understand whether the Alpha and Gamma VOCs are significantly different in these two parameters than the original wildtype of SARS-CoV-2, the most prevalent in relevant areas of Canada as of study initiation. Searches for studies were conducted in Scopus and PubMed, and located through following citations and receiving studies from daily literature scans. For the hospitalization outcome, effect ratios relative to original wildtype were included. For the symptomatic ratio, the ratio itself for each variant was used. Analysis of age-related effects was of particular value, as CAF members are primarily adults under the age of 60. The firmest conclusion of this review is that the Alpha VOC comes with a higher relative risk of hospitalization compared to the original wildtype, most likely above 1.4, while unlikely to be above 2, with the balance of evidence being that the relative risk is not significantly modified by age. The evidence for Gamma is more limited, but the odds ratio may be above 2, and potentially much greater than that, especially for those 20-39 years of age. For both VOCs reports on symptomatic ratio differed on whether there was an effect, as well as its potential direction.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors completed this work as employees of the Department of National Defence. No external funding was received for the work presented.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Defence Research and Development Canada editorial office.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used is in the cited papers.
